Skip to main content

Table 1 Baseline characteristics of chronic hepatitis C patients with thrombocytopenia with or without significant platelet count improvement

From: Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy

Variable All patients (n = 104) With significant platelet count improvement (n = 44) (42.3%) Without significant platelet count improvement (n = 60) (57.7%) P-value
Age (years)a 66.1 (37–88) 64.4 (46–84) 67.8 (37–88) 0.33
Male (%) 40 (38.5%) 12 (27.3%) 28 (46.7%) 0.066
Alcoholism (%) 5 (4.8%) 2 (4.5%) 3 (5%) 1.00
Fatty liver 29 (27.9%) 14 (31.8%) 15 (25.5%) 0.510
ALT(U/L)a 75 (20–492) 71.5 (20–448) 75.0 (20–492) 0.603
AST(U/L)a 54 (10–431) 43.5 (10–410) 58.5 (23–431) 0.194
Albumin (g/dL)a 4.1 (3–5) 4.0 (3–5) 4.1 (3–5) 0.532
Total bilirubin (mg/dL)a 0.80 (0–3) 0.9 (0–2) 0.8 (0–3) 0.971
e-GFR (ml/min/1.73 m2)a 75.7 (4.5–132.1) 75.5 (4.5–118.0) 76.0 (11.9–132.1) 0.594
Platelet (× 103/µL)a 110.5 (32–149) 115.5 (32–149) 106.5 (41–148) 0.932
Prothrombin time (INR)a 1.1 (0.9–1.3) 1.1 (1.0–1.3) 1.1 (0.9–1.3) 0.203
AFP (ng/mL)a 6.0 (2–253) 7.2 (2–253) 5.1 (2–219) 0.064
Baseline HCV viral load (IU/mL)a 1.35 × 106 (176–35.8 × 106) 1.63 × 106 (1890–32.8 × 106) 1.13 × 106 (176–35.8 × 106) 0.453
HCV genotype 1 (%) 71 (68.3%) 32 (72.7%) 39 (65.0%) 0.523
Interferon experienced (%) 31 (29.8%) 16 (36.4%) 15 (25.0%) 0.278
HBV co-infection (%) 5 (4.8%) 2 (4.5%) 3 (5%) 1.00
FIB-4a 4.2 (1.05–20.17) 3.6 (1.05–19.92) 4.9 (1.32–20.17) 0.175
Advanced fibrosis (%) 72 (69.2%) 26 (59.1%) 46 (76.7%) 0.085
HCC history (%) 28 (26.9%) 10 (22.7%) 18 (30.0%) 0.504
Splenomegaly (%) 38 (36.5%) 12 (27.3%) 26 (43.3%) 0.104
Ascites (%) 9 (8.4%) 1 (2.3%) 8 (12.7%) 0.075
TPO (pg/mL)a 132.3 (32.0–3944.0) 172.2 (70.0–3944.0) 74.8 (32.0–3850.0)  < 0.001
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; AFP, alpha-fetoprotein; FIB-4, fibrosis-4; HCC, hepatocellular carcinoma; TPO, thrombopoietin
  2. aData are expressed as median (range)
\